Introduction
There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several landmark studies. However, the patent expiries of two leading products, Singulair and Seretide, will see growth flatten from the turn of the decade.

Scope
Indication based forecasts for asthma/COPD products, with additional coverage of antileukotrienes sales in allergic rhinitis
Assessment of country-specific drivers and resistors likely to impact the market
Future market outlook for individual products taking into account key market events in particular, patent expiries, and competitor launches
Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance
Highlights
Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.

AstraZeneca's Symbicort should become the top-selling brand in the global market, driven by the approval of Symbicort Maintenance and Reliever therapy (SMART) in the EU, the launch of Symbicort in the US market, and the impact of generic competition on Advair/Seretide sales.

Four new launches are expected within the next five years, the most significant being Symbicort in the US and the launch of novel ICS/LABA combination products which will need a strong differentiation profile, based on improved safety, flexible dosing, or once-daily dosing to compete with Advair/Seretide and Symbicort.

Reasons to Purchase
Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products
Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
Capitalize on clinical unmet needs in the market, either through the lifecycle management of marketed drugs or new product development

Introduction
There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several landmark studies. However, the patent expiries of two leading products, Singulair and Seretide, will see growth flatten from the turn of the decade.

Scope
Indication based forecasts for asthma/COPD products, with additional coverage of antileukotrienes sales in allergic rhinitis
Assessment of country-specific drivers and resistors likely to impact the market
Future market outlook for individual products taking into account key market events in particular, patent expiries, and competitor launches
Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance
Highlights
Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.

AstraZeneca's Symbicort should become the top-selling brand in the global market, driven by the approval of Symbicort Maintenance and Reliever therapy (SMART) in the EU, the launch of Symbicort in the US market, and the impact of generic competition on Advair/Seretide sales.

Four new launches are expected within the next five years, the most significant being Symbicort in the US and the launch of novel ICS/LABA combination products which will need a strong differentiation profile, based on improved safety, flexible dosing, or once-daily dosing to compete with Advair/Seretide and Symbicort.

Reasons to Purchase
Identify key environmental opportunities and threats that will impact the use and uptake of new and existing products
Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
Capitalize on clinical unmet needs in the market, either through the lifecycle management of marketed drugs or new product development